Why Is Clearside Biomedical Stock Gaining Today?
Why Is Clearside Biomedical Stock Gaining Today?
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.
Oppenheimer對Clearside Biomedical Inc. (納斯達克股票代碼：CLSD)進行了覆蓋，這是一家專注於通過脈絡膜上（SCS）空間輸送治療方法到眼底的生物製藥公司。
Oppenheimer writes, "We consider Clearside a pioneer in suprachoroidal delivery via its suprachoroidal Microinjector that improves delivery of therapies for retinal diseases."
Oppenheimer寫道，“我們認爲，通過其脈絡膜上微注射器提供的脈絡膜上輸送使Clearside成爲脈絡膜疾病治療領域的先驅。”
Suprachoroidal drug delivery is an ocular route of drug administration.
脈絡膜上藥物輸送是一種眼部用藥途徑。
The analyst writes that intravitreal injections have traditionally been the standard for delivering retinal treatments, but they can cause issues like uncontrolled dispersion.
分析師寫道，玻璃體內注射傳統上一直是輸送視網膜治療的標準，但其會導致無法控制的擴散等問題。
Meanwhile, SCS injections provide a more targeted and compartmentalized delivery directly into the chorioretinal tissues, ensuring high concentrations and extended effectiveness.
同時，SCS注射提供了更有針對性和隔離性的輸送，直接進入脈絡膜和視網膜組織，確保高濃度和長效。
Oppenheimer has initiated the coverage with an Outperform rating and a price target of $5.
Oppenheimer以跑贏市場爲評級標準，給出了5美元的價格目標，並開始對Clearside Biomedical進行覆蓋。
Clearside Biomedical has five ongoing collaborations and is advancing its wholly-owned CLS-AX program, a proprietary suspension formulation of axitinib for wet age-related macular degeneration (wet AMD).
Clearside Biomedical擁有5個正在進行的合作項目，並推進其完全擁有的CLS-AX項目，這是一種用於治療溼性年齡相關性黃斑變性（溼性AMD）的專有懸浮劑製劑。
Moreover, ongoing strategic partnerships with Bausch + Lomb Corp (NYSE:BLCO) and REGENXBIO Inc (NASDAQ:RGNX) further validate the SCS Microinjector platform.
此外，與Bausch + Lomb Corp（紐交所：BLCO）和REGENXBIO Inc（納斯達克股票代碼：RGNX）的持續戰略合作進一步驗證了SCS微注射器平台。
With Clearside Biomedical shares trading at a discount to peers, Oppenheimer sees an opportunity for meaningful appreciation with positive results from the upcoming Phase 2b ODYSSEY in wet AMD in the third quarter of 2024.
由於Clearside Biomedical股票交易價格低於同行業公司，因此Oppenheimer認爲，在2024年第三季度溼性AMD ODYSSEY的積極成果下，Clearside Biomedical有很大的升值機會。
Sales of the top-selling treatments underscore the significant market potential for effective wet AMD treatments.
暢銷治療的銷售額突顯了有效溼性AMD治療的巨大市場潛力。
The global ophthalmic drugs market was valued at approximately $42.8 billion in 2022 and is projected to reach $59.1 billion by 2028.
全球眼科藥物市場價值約爲428億美元，預計到2028年將達到591億美元。
Clearside's strategic partnerships and the expansion of XIPERE into other indications (uveitic macular edema and diabetic macular edema) enhance its development capabilities and market reach, validating its technology and approach.
Clearside的戰略合作伙伴以及XIPERE擴展到其他適應症（葡萄膜炎性黃斑水腫和糖尿病性黃斑水腫）增強了其開發能力和市場覆蓋範圍，驗證了其技術和方法。
Oppenheimer writes, "With its unique broad mechanism of action inhibition, targeted delivery method, and strategic collaborations, Clearside is well positioned for success."
Oppenheimer寫道，“憑藉其獨特的廣泛作用機制、有針對性的輸送方式和戰略合作，Clearside已經爲成功做好了充分準備。”
Price Action: CLSD shares are up 14.35% at $1.23 at last check Tuesday.
CLSD股票最近交易價格爲每股1.23美元，上漲14.35%。
Photo by Amanda Dalbjörn on Unsplash
照片由Amanda Dalbérg引用Unsplash。
譯文內容由第三人軟體翻譯。